Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Average Price Target from Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHAGet Free Report) have been assigned an average recommendation of “Buy” from the eight analysts that are presently covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $6.63.

Several analysts have recently issued reports on the company. JMP Securities restated a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Chardan Capital reiterated a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Thursday, November 14th. Canaccord Genuity Group upped their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th.

Check Out Our Latest Analysis on Taysha Gene Therapies

Institutional Trading of Taysha Gene Therapies

Several institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its position in Taysha Gene Therapies by 23.7% during the third quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock valued at $7,163,000 after acquiring an additional 682,273 shares during the period. State Street Corp increased its position in Taysha Gene Therapies by 4.5% during the 3rd quarter. State Street Corp now owns 3,469,068 shares of the company’s stock worth $6,973,000 after purchasing an additional 150,647 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Taysha Gene Therapies by 1.3% in the third quarter. JPMorgan Chase & Co. now owns 3,001,397 shares of the company’s stock valued at $6,033,000 after buying an additional 37,844 shares during the period. Quantum Private Wealth LLC lifted its position in Taysha Gene Therapies by 5.1% during the third quarter. Quantum Private Wealth LLC now owns 767,616 shares of the company’s stock valued at $1,543,000 after buying an additional 37,096 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new stake in Taysha Gene Therapies during the third quarter worth approximately $931,000. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies Price Performance

TSHA stock opened at $1.73 on Thursday. The stock’s 50 day moving average price is $2.11 and its 200 day moving average price is $2.19. The firm has a market cap of $354.55 million, a P/E ratio of 2.75 and a beta of 0.79. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. Taysha Gene Therapies has a 1 year low of $1.19 and a 1 year high of $4.32.

About Taysha Gene Therapies

(Get Free Report

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

Featured Articles

Analyst Recommendations for Taysha Gene Therapies (NASDAQ:TSHA)

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.